StageZero Life Sciences (GNWSD) Stock Price, News & Analysis

Company Overview

StageZero Life Sciences Ltd is a clinical-stage biotechnology company dedicated to the development and commercialization of non-invasive blood tests for the early detection of cancer. The company’s proprietary biomarker platform is designed to identify DNA methylation signatures and other molecular indicators associated with multiple tumour types in circulating cell-free DNA, aiming to detect malignancies at pre-symptomatic stages.

StageZero’s pipeline includes assays targeting colorectal, lung and other solid-tumour cancers. By integrating next-generation sequencing technologies with advanced bioinformatics and machine-learning algorithms, the company seeks to achieve high sensitivity and specificity, thereby supporting timely clinical decision-making and personalized screening programs for both average-risk and high-risk populations.

To validate its screening tests, StageZero collaborates with academic research centres and healthcare providers across North America, conducting pilot programs and clinical utility studies. These partnerships are aimed at establishing real-world performance benchmarks, generating data for regulatory submissions and facilitating broader adoption of its tests in hospital and laboratory settings.

The company is led by a management team with extensive experience in molecular diagnostics, oncology research and regulatory affairs, alongside a board of independent directors versed in biotechnology finance and commercialization. This leadership structure underpins StageZero’s strategic focus on transitioning its diagnostic platforms from development through to clinical implementation.

Key Stats

• Today's Range: $0.0010 to $0.0010
• 50-Day Range: N/A
• 52-Week Range: $0.17 to $0.89
• Volume: N/A
• Average Volume: 4,987 shs
• Market Capitalization: $48.94 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:GNWSD
• CIK: N/A
• Web: www.stagezerolifesciences.com
• Phone: (855) 420-7140
• Fax: N/A
• Employees: 80
• Year Founded: 1998

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.48 million
• Net Margins: 217.39%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -61.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.09
• Quick Ratio: 0.06

Sales & Book Value

• Annual Sales: $140 thousand
• Price / Sales: 0.35
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.13) per share
• Price / Book: -0.01

Miscellaneous

• Outstanding Shares: 48,940,000
• Free Float: N/A
• Market Cap: $48.94 thousand
• Optionable: Not Optionable
• Beta: 2.97